RMD Maintained by Keybanc -- Price Target Raised to $267

gurufocus.com · 2026-08-31

On October 05, 2023, ResMed (RMD) has been maintained with an Overweight rating by Keybanc's analyst Brett Fishbin. The price target has been raised from $255.0

TickrTrends take: Keybanc's decision to maintain its stance on RMD while raising the price target to $267 suggests analyst confidence in the company's fundamental trajectory within the Healthcare sector. Given TickrTrends' current assessment that RMD trades at an undervalued level, the raised price target may reflect growing conviction that the market has not fully priced in the company's earnings potential or competitive positioning. Valuation-focused investors should monitor whether RMD's actual trading price moves toward the $267 target, as this would indicate whether the current undervaluation thesis is closing.

Read the full story at gurufocus.com →